Urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 and type 2 in stage I malignant melanoma

Oncology Reports

Volumn 10, Issue 3, 2003, Pages 635-639

  Stabuc, Borut ^a   Markovic, Jasmina ^a   Bartenjev, Igor ^a   Vrhovec, Ivan ^b   Medved, Urska ^a   Kocltancic, Borut ^a  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^b INSTITUTE OF ONCOLOGY   (Slovenia)

Author keywords

Malignant melanoma; PAI 1; PAI 2; uPA

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; UROKINASE;

ADULT; AGED; ARTICLE; CANCER INVASION; COMPARATIVE STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; MELANOMA; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SKIN; SKIN TUMOR; VASCULAR TUMOR;

ADULT; AGED; AGED, 80 AND OVER; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM INVASIVENESS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; PROGNOSIS; SKIN; SKIN NEOPLASMS; URINARY PLASMINOGEN ACTIVATOR; VASCULAR NEOPLASMS;

EID: 0642375754     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Slominski A, Ross J, Mihm MC, et al: Cutaneous melanoma: pathology, relevant prognostic indicators and progression. Br Med Bull 51: 548-569, 1995.
2. Andreasen PA, Kjøller L, Christensen L, et al: The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 72: 1-22, 1997. (Pubitemid 27314632)
3. Schmitt M, Harbeck N, Thomssen C, et al: Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb Haemost 78: 285-296, 1997. (Pubitemid 27289256)
4. Reuning U, Magdolen V, Wilhelm O, et al: Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis. Int J Oncol 13: 893-906, 1998. (Pubitemid 28506055)
5. Duffy MJ, Maguire TM, McDermott EW, et al: Urokinase plasminogen activator: a prognostic marker in multiple types of cancer. J Surg Oncol 71: 130-135, 1999. (Pubitemid 29288493)
6. Quax PHA, Van Muijen GNP, Weening-Verhoeff EJD, et al: Metastatic behaviour of human melanoma cell lines in nude mice correlates with urokinase-type plasminogen activator, its type-1 inhibitor and urokinase mediated matrix degradation. J Cell Biol 115: 191-199, 1992. (Pubitemid 21909905)
7. De Vries TJ, Quax PHA, Denijn M, et al: Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression. Am J Pathol 144: 70-81, 1994. (Pubitemid 24158361)
8. American Joint Committee on Cancer: Manual for Staging of Cancer. JB Lippincott Co., Philadelphia, 1997.
9. Benraad TJ, Geurts-Moespot J, Grøndahl-Hansen J, et al: Immunoassays (ELISA) of urokinase-type plasminogen activator (uPA): report of an EORTC/BIOMED-1 workshop. Eur J Cancer 32A, No. 8: 1371-1381, 1996.
10. Fräki JE, Nieminen S, Hopsu-Havu VK, et al: Proteolytic enzymes and plasminogen activators in melanoma. J Cutan Pathol 6: 195-200, 1979. (Pubitemid 9230741)
11. De Vries TJ, Mooy CM, van Balken MR, et al: Components of the plasminogen activation system in uveal melanoma - a clinico - pathological study. J Pathol 175: 59-67, 1995.
12. Delbaldo C, Masouye I, Saurat JH, et al: Plasminogen activation in melanocytic neoplasia. Cancer Res 54: 4547-4552, 1994. (Pubitemid 24273175)
13. Ferrier CM, De Witte HH, Straatman H, et al: Comparison of immunohistochemistry with immunoassay (ELISA) for the detection of components of the plasminogen activation system in human tumour tissue. Br J Cancer 79: 1534-1541, 1999. (Pubitemid 29116817)
14. Ferrier CM, Suciu S, van Geloof WL, et al: High tPA-expression in primary melanoma of the limb correlates with good prognosis. Br J Cancer 83: 1351-1359, 2000.
15. Sweep CG, Geurts-Moespot J, Grebenschikov N, et al: External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts. Br J Cancer 78: 1434-1441, 1998. (Pubitemid 28517539)
16. Foekens JA, Buessecker F, Peters HA, et al. Plasminogen activator inhibitor-2: prognostic relevance in 1012 patients with primary breast cancer. Cancer Res 55: 1423-1427, 1995.
17. Nekarda H, Schmitt M, Ulm K, et al: Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Res 54: 2900-2907, 1994. (Pubitemid 24187770)
18. Ganesh S, Sier CFM, Griffioen G, et al: Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer. Cancer Res 54: 4065-4071, 1994. (Pubitemid 24258110)
19. Wei Y, Lukashev M, Simon DI, et al: Regulation of integrin function by the urokinase receptor. Science 273: 1551-1555, 1996. (Pubitemid 26301666)
20. Schmitt M, Wilhelm OG, Reuning U, et al: The urokinase plasminogen activator system as a novel target tumor therapy. Fibrinol Proteol 14: 114-132, 2000. (Pubitemid 30409285)